International Biotechnol... Dividends - IBT

International Biotechnol... Dividends - IBT

Best deals to access real time data!
Level 2 Basic
Monthly Subscription
for only
Monthly Subscription
for only
UK/US Silver
Monthly Subscription
for only
VAT not included
Stock Name Stock Symbol Market Stock Type Stock ISIN Stock Description
International Biotechnology Trust Plc IBT London Ordinary Share GB0004559349 ORD 25P
  Price Change Price Change % Stock Price Last Trade
17.50 2.38% 753.00 16:35:22
Open Price Low Price High Price Close Price Previous Close
744.00 743.00 750.00 753.00 735.50
more quote information »
Industry Sector

International Biotechnol... IBT Dividends History

Announcement Date Type Currency Dividend Amount Period Start Period End Ex Date Record Date Payment Date Total Dividend Amount

Top Dividend Posts

speedsgh: Carl Harald Janson is stepping back from his role as Lead Investment Manager to be replaced by existing investment mansgers Ailsa Craig & Marek Poszepczynski... Appointment of Joint Lead Investment Managers - HTTPS://
speedsgh: Dividend Declaration - HTTPS:// At the Annual General Meeting held on 15 December 2020, Shareholders approved the Company's dividend policy of making dividend payments, equivalent to 4 per cent. of the Company's Net Asset Value as at the last day of the preceding financial year (31 August), through two equal semi-annual distributions. The Directors have today declared the first Interim Dividend for the period ending 31 August 2021 in an amount of 14.2p per Ordinary Share. The first Interim Dividend will be payable on Friday, 29 January 2021 to holders of Ordinary Shares on the Register at the close of business on Tuesday, 29 December 2020 (ex-dividend Thursday, 24 December 2020).
shieldbug: Not so pleased to see how they calculate the dividend though. The 4% is calculated once a year and divided into two payments. So we don't get 2% of the mid July price.
shieldbug: This year IBT bought back about £1m of shares (172,546 shares) at an average price of £5.82 and have just issued 75,000 shares at £7.94. Rarely see great benefit from buy backs but that looks impressive.
speedsgh: Yes, it would appear that the benefits of the attractive dividend policy have been more than nullified by NAV performance where IBT has noticeably lagged its peers over the past 5yrs. It would certainly be pleasing to see that change. The irony of course is that the discount to NAV has narrowed significantly over the same time period.
mozy123: Quite disappointing, other healthcare/bio trusts on the move over the last few months. IBT nothing. Nothing for a fair few years, hopefully a rocket has been ignited somewhere in the portfolio.
speedsgh: Dividends, buybacks, share issuance and discount I am pleased to report that the Company's fifth and sixth dividend payments were made during the financial year. We paid out a dividend equal to 4% of NAV as at 31 August 2018 in two equal tranches on 31 January 2019 and 31 August 2019, equating to a 4.1% increase when compared with dividend payments in the previous year. In accordance with the Shareholder Circular dated 13 September 2016 and as a matter of best practice, the Board will be seeking Shareholder approval to continue the payment of dividends and a resolution will be put to Shareholders at the forthcoming Annual General Meeting (AGM)...
shieldbug: IBT hit by pound strengthening and dividend payout?
speedsgh: According to the most recent monthly factsheet, the NAV as at financial year end on 31/8/2019 was £239m (622p per share). HTTPS:// Current dividend policy is to pay out an amount eqivalent to 4% of yr end NAV in two tranches. NAV as at 31/8/2018 was 699p which equated to a dividend of 28.0p in the current FY (2 x 14.0p payments) If NAV as at 31/8/2019 was 622p, this would appear to equate to a dividend of 24.75-25.0p over the next 12 months, which would represent a reduction of c.11-12%.
davebowler: QuoteData- Beating the odds view report Strategic positioning in mid-2018 helped International Biotechnology Trust (IBT) beat its benchmark over the past six months and close its discount to net asset value (NAV). This continued its outperformance of the US Nasdaq Biotechnology Index (NBI) over three and five years. Active management of the portfolio and an increased focus on larger mid-caps played out well in terms of IBT’s performance versus its peers. IBT’s manager is maintaining its established policy of active risk mitigation, designed to avoid exposure to binary events that can cause large swings in the share price (typically the results of the Phase III trials that provide the final confirmation of safety and efficacy before the FDA approves a treatment for marketing). This should be seen as another attraction to investors in the trust. IBT’s shares have recently moved to trade at a premium to NAV and it has been issuing stock, expanding the fund. SECTOR: SECTOR SPECIALIST - BIOTECHNOLOGY AND HEALTHCARE TICKER: IBT LN BASE CURRENCY: GBP (PENCE) PRICE: 634.00P NAV: 636.40P PREMIUM/(DISCOUNT): (0.4%) YIELD: 4.4% spacer spacer spacer ACCESS TO THE FAST-GROWING BIOTECH SECTOR charticon spacer spacer spacer spacer IBT is the longest-established of the London-listed funds specialising in the biotech/healthcare sector. It aims to achieve long-term capital growth by investing in biotechnology and other life sciences companies, and offers investors the highest yield in the sector while keeping its day-to-day running costs low. The portfolio is invested primarily in quoted companies, but IBT also has some exposure to unquoted compani
ADVFN Advertorial
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210423 05:28:56